joining the dots of recent obj announcements, page-9

This is my opinion and or theory if you like on the 3 more advanced partner programs that have already been announced to the market coppertop:
___

#1 - Major International FMCG Company

I believe this partnership was intended to represent the first of the very lucrative deals for OBJ as it utilzes both our DP and ETP technologies for an existing OTC drug with multi-billion dollar international sales (as already advised to the market) however I also believe that there may be current delays with the marketing approval which may be due to a number of reasons including the slow regulatory process, ETP patent acceptance etc etc...

"In 2007 OBJ executed a Collaboration Agreement with the major international FMCG company to explore the use of ETP and DP with two compounds for overthe-counter (OTC) use. This initial program was completed in March 2008 and in December 2008 the Company announced a second and larger technology optimization program, to be conducted in the USA at a facility operated by Azopharma Contract Services Inc. OBJ received approximately US$335,000 for the program. The outcomes of that program were summarized in the release to shareholders in October 2009 and indicated that the Company’s technology had achieved the FMCG company’s stated objectives. Since that time OBJ has continued to work with the FMCG company in the development of a product to enhance the delivery of one of their key therapeutic agents, and the Statement of Intent represents a continuation of that relationship."

As I've also speculated on a number of occasions that I believe there has been a number of indications to believe a licence agreement has already been signed with this same FMCG partner sometime last year. The following statement from a 2008 announcement only adds further to this speculation imo.

October 2008 - OBJ SIGNS SECOND AGREEMENT WITH GLOBAL FMCG COMPANY
The terms of the agreement and details of the feasibility project are subject to confidentiality; however OBJ will receive fees of up to US$335,000 for completion of the project. The agreement also deals with future collaboration and potential licensing rights that may arise following a successful feasibility.
__________

#2 - GlaxoSmithKline

We're all well aware of the continued success reported for the GSK collaborative development agreement in Oral Healthcare and imo OBJ's next big announcement will come from GSK updating the progress of the advanced clinical programs in this area.

I also continue to believe that OBJ remain a major collaborater with Glaxo in more than one other area of healthcare and I also believe OBJ's technology will play a major part in the future of GSK's vaccine portfolio which will include one of GSK's major strategies of providing low cost medicines to the world's poorest nations.
__________

#3 - Strategic Alliance with Global FMCG Company

"The potential personal care applications for magnetic arrays have continued to receive substantial interest from several FMCG and prestige cosmetic companies. A key achievement in this area was the announcement in September 2010, of a Strategic Alliance program with one of the world's largest FMCG companies. Work on this latter program has proved particularly encouraging, with magnetic array technology now demonstrated to improve the delivery of several key therapeutic agents - both ex vivo and in vivo. The most effective approach to bringing one or more applications to market is now the focus of discussions.

Negotiations have now commenced to secure Access Rights to Beauty Care for all 3 of our technology platforms - this speaks very loud and clear imo.

I also continue to speculate that 3M remain a major part of this Strategic Alliance partnership - more so than just playing a manufacturing role.

Also, although I don't think it's been discussed here I'm not expecting OBJ to receive upfront license fees or milestone payments from this Strategic Alliance as it's to my understanding that a JDA is an agreement whereby all parties agree to share the risk through to product commercialisation, however as a result I believe the royalty payments negotiated on all future product sales will represent a higher double digit percentage figure.

Happy to hear any objective opinions on this subject.
__________

I no longer need to suggest it's only an opinion that OBJ have many other coals burning in the fire with an expanding number of major international players, as they have continued to advise the market of this in more recent announcements, however I believe it's fair to assume many of these are still going through the earlier stage evaluation phases and like our own recently announced Pain Patch program, may still be 2 or more years away from a commercial outcome... with the only exception being those new players involved in the development of personal, homecare or hygiene products utilizing OBJ's ETP and FIM technologies.

On that note did anyone find the following statement in our Annual Report was delivered with some careful but deliberate ambiguity? I certainly did.

"Homecare and Hygiene applications were new areas of consideration last year, but along with personal care these areas offer opportunities for a shorter time to market."

"... were new areas of consideration last year, but along with personal care..." expect us to soon announce a short term commercial outcome??